[A CASE OF UNRESECTABLE METASTATIC RENAL CARCINOMA SUCCESSFULLY TREATED BY COMBINED MODALITY THERAPY WITH NIVOLUMAB...

Area of Science:

• Oncology
• Immunotherapy
• Nephrology

Background:

• Advanced renal cell carcinoma (RCC) presents significant treatment challenges.
• Metastatic RCC often requires systemic therapy for unresectable disease.

Observation:

• A 65-year-old male with stage IV RCC (cT4N1M1b) showed progression on pazopanib.
• Initial nivolumab treatment caused temporary mobility issues due to vertebral metastases.
• Disease stabilization allowed resumption of nivolumab therapy.

Findings:

• Nivolumab treatment resulted in a 70% reduction of the primary renal tumor.
• Significant tumor regression or disappearance was observed in lung and bone metastases.
• Neoadjuvant nivolumab therapy rendered the previously unresectable tumor amenable to radical nephrectomy.

Implications:

• Nivolumab demonstrates efficacy as a neoadjuvant therapy for advanced, unresectable renal cell carcinoma.
• This case highlights the potential for immunotherapy to convert unresectable tumors to a resectable state.
• Successful conversion to surgical resection after immunotherapy offers a new treatment paradigm for advanced RCC.